MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial

OBJECTIVES: To determine the safety, tolerability and signs of efficacy of MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor (GM-CSF), in patients with rheumatoid arthritis (RA). METHODS: Patients with active, moderate RA were enrolled in a randomised, multicent...

Descripción completa

Detalles Bibliográficos
Autores principales: Behrens, Frank, Tak, Paul P, Østergaard, Mikkel, Stoilov, Rumen, Wiland, Piotr, Huizinga, Thomas W, Berenfus, Vadym Y, Vladeva, Stoyanka, Rech, Juergen, Rubbert-Roth, Andrea, Korkosz, Mariusz, Rekalov, Dmitriy, Zupanets, Igor A, Ejbjerg, Bo J, Geiseler, Jens, Fresenius, Julia, Korolkiewicz, Roman P, Schottelius, Arndt J, Burkhardt, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431325/
https://www.ncbi.nlm.nih.gov/pubmed/24534756
http://dx.doi.org/10.1136/annrheumdis-2013-204816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431325/
https://www.ncbi.nlm.nih.gov/pubmed/24534756
http://dx.doi.org/10.1136/annrheumdis-2013-204816

Ejemplares similares